Sunosi (solriamfetol) for ADHD?

In November 2013 the first controlled study of solriamfetol (Sunosi) for ADHD was published, with encouraging results about its tolerability and efficacy in treating ADHD. Phase 3 trials of this dopamine and norepinephrine reuptake inhibitor for the treatment of ADHD started in July 2023. Industry experts anticipate that in a year or two the drug may receive approval for treating ADHD.

The FDA approved Sunosi for excessive daytime sleepiness from narcolepsy or obstructive sleep apnea a few years ago (2019). So far, Sunosi seems safer than stimulants, and more effective than modafinil in improving daytime alertness in these conditions. Whether Sunosi turns out to be more effective than bupropion (Wellbutrin, Forfivo, Aplenzin) in the treatment of ADHD remains to be seen. The preliminary data suggests that benefits of solriamfetol for ADHD are not simply due to decreasing daytime sleepiness.

References:
Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study (2023)
https://www.psychiatrist.com/jcp/solr...

Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy (2022)
https://www.sciencedirect.com/science...

Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea (2021)
https://pubmed.ncbi.nlm.nih.gov/34402...

A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor
https://www.ncbi.nlm.nih.gov/pmc/arti...

General:
Psychiatrist, neuroscientist, and author John Kruse, MD, PhD presents practical, actionable, well-researched information about treatment options that scientists and clinicians recommend for adult ADHD and other mental health conditions. Subscribe if you're curious about how neuro-atypical brains can optimize their functioning in our shared, and somewhat strange, world.

Dr. Kruse has posted talks in both the "live" and the "video" sections of this channel. Thumbnails on ADHD topics have a pink background, and those on more general mental health topics have a purple background. A small collection of ADHD-Trump videos have an orange background.

You're welcome to email him with topics you want discussed, people you think he should interview, or if you would prefer a time for the weekly YouTube Live option other than Tuesdays at 6:00 pm (Pacific Standard Time).